Profile change history

What changed for Leuprolide?

A deterministic history of records added to PeptideScanner and preserved profile or record revisions connected through the reviewed Leuprolide identity.

236Total events
232Record additions
4Version changes
32Cited source years

Before and after

Preserved version changes

Record updated

ClinicalTrials.gov record NCT05669664

ClinicalTrials.gov posted a newer version of NCT05669664, with a registry update date of 2026-11-16. This version reports that observation; the earlier retained observation remains available as version 1.

PeptideScanner change date
November 16, 2026
Cited source date
November 16, 2026
Evidence lane
Clinical trials

Summary

Before
PeptideScanner retained ClinicalTrials.gov record NCT05669664 at 2026-07-30T16:19:03.066Z. Its registry update date was 2026-06-17, and PeptideScanner's reviewed identity mapping was leuprolide.
After
PeptideScanner retained ClinicalTrials.gov record NCT05669664 at 2026-11-16T13:28:59.838Z. Its registry update date was 2026-11-16, and PeptideScanner's reviewed identity mapping was leuprolide.

Cited source date

Before
2026-06-17
After
2026-11-16

Source observed date

Before
2026-07-30
After
2026-11-16

Cited source records

Before
ctg-observation-nct05669664-2026-06-17-1cc9e92daca2
After
ctg-observation-nct05669664-2026-06-17-1cc9e92daca2-r2

Headline citations

Before
ctg-observation-nct05669664-2026-06-17-1cc9e92daca2
After
ctg-observation-nct05669664-2026-06-17-1cc9e92daca2-r2

Summary citations

Before
ctg-observation-nct05669664-2026-06-17-1cc9e92daca2
After
ctg-observation-nct05669664-2026-06-17-1cc9e92daca2-r2

Attributable context

Before
1. PeptideScanner retained ClinicalTrials.gov record NCT05669664 at 2026-07-30T16:19:03.066Z. Its registry update date was 2026-06-17, and PeptideScanner's reviewed identity mapping was leuprolide. [sources: ctg-observation-nct05669664-2026-06-17-1cc9e92daca2] 2. This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. [sources: ctg-observation-nct05669664-2026-06-17-1cc9e92daca2]
After
1. PeptideScanner retained ClinicalTrials.gov record NCT05669664 at 2026-11-16T13:28:59.838Z. Its registry update date was 2026-11-16, and PeptideScanner's reviewed identity mapping was leuprolide. [sources: ctg-observation-nct05669664-2026-06-17-1cc9e92daca2-r2] 2. This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. [sources: ctg-observation-nct05669664-2026-06-17-1cc9e92daca2-r2]

Source snapshot commitment

Before
89e592b23c98d73045c9944adc28bbf5c628a3ebc7d2a85512423412fd1ca5c5
After
b3a5ff90419c4c0a50b967a4dcdb2433c975a8120c2f378701ac9c463645c350
Profile updated

Leuprolide profile

We re-based this profile on the current Eligard label on DailyMed (SPL version 19, published May 11, 2026), because the generic label cited before is no longer marketed or served, and now describe the studies that label reports. HERO is described only as a trial in which leuprolide was the comparison treatment. Earlier versions remain available.

PeptideScanner change date
November 15, 2026
Evidence lane
Profile

Profile summary

Before
A GnRH agonist FDA-approved since 1985 under several names. The cited label covers palliative treatment of advanced prostate cancer; FDA approved Vobrig for central precocious puberty in August 2026.
After
A GnRH agonist FDA-approved since 1985 under several names. The cited Eligard label covers advanced prostate cancer; FDA approved Vobrig for central precocious puberty in August 2026.

Evidence note

Before
The label describes a controlled comparison with another hormone treatment in prostate cancer, and leuprolide served as the comparison treatment in a large randomized trial. Each leuprolide product has its own label and uses.
After
The cited Eligard label describes four open-label studies that measured testosterone suppression in men with prostate cancer. Each leuprolide product has its own label and uses.

Cited source records

Before
dailymed-leuprolide-4838c674-044e-46b2-81e7-c691b99d8fa5-v10, fda-drugs-nda019010-1985-04-09-d97355079c93, fda-drugs-nda019732-1989-01-26-f4233297ff5a, fda-drugs-nda020263-1993-04-16-d5ec3f5822e0, fda-drugs-nda021343-2002-01-23-f17a5edda965, fda-drugs-nda213150-2020-05-01-40513bba6c48, fda-vobrig-approval-2026, journal-pmid-32469183
After
dailymed-leuprolide-b7b679a9-6823-4ef8-8d31-3ab5058ffcfc-v19, fda-drugs-nda019010-1985-04-09-d97355079c93, fda-drugs-nda019732-1989-01-26-f4233297ff5a, fda-drugs-nda020263-1993-04-16-d5ec3f5822e0, fda-drugs-nda021343-2002-01-23-f17a5edda965, fda-drugs-nda213150-2020-05-01-40513bba6c48, fda-vobrig-approval-2026, journal-pmid-32469183, fda-drugs-nda213225-2026-08-26-94e1fef9b739

Named organizations

Before
U.S. National Library of Medicine [sources: dailymed-leuprolide-4838c674-044e-46b2-81e7-c691b99d8fa5-v10]; U.S. Food and Drug Administration [sources: fda-drugs-nda019010-1985-04-09-d97355079c93, fda-vobrig-approval-2026]
After
U.S. National Library of Medicine [sources: dailymed-leuprolide-b7b679a9-6823-4ef8-8d31-3ab5058ffcfc-v19]; U.S. Food and Drug Administration [sources: fda-drugs-nda019010-1985-04-09-d97355079c93, fda-vobrig-approval-2026]

Claim citations

Before
name: dailymed-leuprolide-4838c674-044e-46b2-81e7-c691b99d8fa5-v10; aliases: dailymed-leuprolide-4838c674-044e-46b2-81e7-c691b99d8fa5-v10, fda-drugs-nda019010-1985-04-09-d97355079c93, fda-drugs-nda021343-2002-01-23-f17a5edda965, fda-vobrig-approval-2026; category: dailymed-leuprolide-4838c674-044e-46b2-81e7-c691b99d8fa5-v10; status: dailymed-leuprolide-4838c674-044e-46b2-81e7-c691b99d8fa5-v10, fda-drugs-nda019010-1985-04-09-d97355079c93, fda-drugs-nda019732-1989-01-26-f4233297ff5a, fda-drugs-nda021343-2002-01-23-f17a5edda965, fda-vobrig-approval-2026; summary: dailymed-leuprolide-4838c674-044e-46b2-81e7-c691b99d8fa5-v10, fda-drugs-nda019010-1985-04-09-d97355079c93, fda-vobrig-approval-2026; evidenceNote: dailymed-leuprolide-4838c674-044e-46b2-81e7-c691b99d8fa5-v10, journal-pmid-32469183
After
name: dailymed-leuprolide-b7b679a9-6823-4ef8-8d31-3ab5058ffcfc-v19; aliases: dailymed-leuprolide-b7b679a9-6823-4ef8-8d31-3ab5058ffcfc-v19, fda-drugs-nda019010-1985-04-09-d97355079c93, fda-drugs-nda021343-2002-01-23-f17a5edda965, fda-vobrig-approval-2026; category: dailymed-leuprolide-b7b679a9-6823-4ef8-8d31-3ab5058ffcfc-v19; status: dailymed-leuprolide-b7b679a9-6823-4ef8-8d31-3ab5058ffcfc-v19, fda-drugs-nda019010-1985-04-09-d97355079c93, fda-drugs-nda019732-1989-01-26-f4233297ff5a, fda-drugs-nda021343-2002-01-23-f17a5edda965, fda-vobrig-approval-2026, fda-drugs-nda213225-2026-08-26-94e1fef9b739; summary: dailymed-leuprolide-b7b679a9-6823-4ef8-8d31-3ab5058ffcfc-v19, fda-drugs-nda019010-1985-04-09-d97355079c93, fda-drugs-nda021343-2002-01-23-f17a5edda965, fda-vobrig-approval-2026; evidenceNote: dailymed-leuprolide-b7b679a9-6823-4ef8-8d31-3ab5058ffcfc-v19
Profile status changed

Leuprolide profile

We added a plain-language reader guide with cited answers, Drugs@FDA approval records for leuprolide products, FDA’s August 26, 2026 approval of Vobrig for central precocious puberty, and the HERO trial. DailyMed no longer serves the cited label version, so we checked it against the current rendering of the same label set.

PeptideScanner change date
November 14, 2026
Evidence lane
Profile

Status

Before
U.S. label record
After
FDA-approved as Lupron, Eligard, Vobrig and other leuprolide products

Profile summary

Before
A GnRH agonist. This profile cites a U.S. label record.
After
A GnRH agonist FDA-approved since 1985 under several names. The cited label covers palliative treatment of advanced prostate cancer; FDA approved Vobrig for central precocious puberty in August 2026.

Evidence note

Before
The cited DailyMed label identifies Leuprolide and contains the product's official indications and warnings. This profile links to the label without restating it as medical guidance.
After
The label describes a controlled comparison with another hormone treatment in prostate cancer, and leuprolide served as the comparison treatment in a large randomized trial. Each leuprolide product has its own label and uses.

Related names

Before
Leuprolide acetate
After
Leuprolide acetate, Lupron, Eligard, Vobrig

Cited source records

Before
dailymed-leuprolide-4838c674-044e-46b2-81e7-c691b99d8fa5-v10
After
dailymed-leuprolide-4838c674-044e-46b2-81e7-c691b99d8fa5-v10, fda-drugs-nda019010-1985-04-09-d97355079c93, fda-drugs-nda019732-1989-01-26-f4233297ff5a, fda-drugs-nda020263-1993-04-16-d5ec3f5822e0, fda-drugs-nda021343-2002-01-23-f17a5edda965, fda-drugs-nda213150-2020-05-01-40513bba6c48, fda-vobrig-approval-2026, journal-pmid-32469183

Named organizations

Before
U.S. National Library of Medicine [sources: dailymed-leuprolide-4838c674-044e-46b2-81e7-c691b99d8fa5-v10]
After
U.S. National Library of Medicine [sources: dailymed-leuprolide-4838c674-044e-46b2-81e7-c691b99d8fa5-v10]; U.S. Food and Drug Administration [sources: fda-drugs-nda019010-1985-04-09-d97355079c93, fda-vobrig-approval-2026]

Claim citations

Before
name: dailymed-leuprolide-4838c674-044e-46b2-81e7-c691b99d8fa5-v10; aliases: dailymed-leuprolide-4838c674-044e-46b2-81e7-c691b99d8fa5-v10; category: dailymed-leuprolide-4838c674-044e-46b2-81e7-c691b99d8fa5-v10; status: dailymed-leuprolide-4838c674-044e-46b2-81e7-c691b99d8fa5-v10; summary: dailymed-leuprolide-4838c674-044e-46b2-81e7-c691b99d8fa5-v10; evidenceNote: dailymed-leuprolide-4838c674-044e-46b2-81e7-c691b99d8fa5-v10
After
name: dailymed-leuprolide-4838c674-044e-46b2-81e7-c691b99d8fa5-v10; aliases: dailymed-leuprolide-4838c674-044e-46b2-81e7-c691b99d8fa5-v10, fda-drugs-nda019010-1985-04-09-d97355079c93, fda-drugs-nda021343-2002-01-23-f17a5edda965, fda-vobrig-approval-2026; category: dailymed-leuprolide-4838c674-044e-46b2-81e7-c691b99d8fa5-v10; status: dailymed-leuprolide-4838c674-044e-46b2-81e7-c691b99d8fa5-v10, fda-drugs-nda019010-1985-04-09-d97355079c93, fda-drugs-nda019732-1989-01-26-f4233297ff5a, fda-drugs-nda021343-2002-01-23-f17a5edda965, fda-vobrig-approval-2026; summary: dailymed-leuprolide-4838c674-044e-46b2-81e7-c691b99d8fa5-v10, fda-drugs-nda019010-1985-04-09-d97355079c93, fda-vobrig-approval-2026; evidenceNote: dailymed-leuprolide-4838c674-044e-46b2-81e7-c691b99d8fa5-v10, journal-pmid-32469183
Profile updated

Leuprolide profile

We rewrote the profile summary to describe the cited public record more directly. The cited sources and status did not change.

PeptideScanner change date
July 27, 2026
Evidence lane
Profile

Profile summary

Before
A GnRH agonist represented by one exact U.S. label record.
After
A GnRH agonist. This profile cites a U.S. label record.

Collection chronology

Evidence added to PeptideScanner

Browse all 232 connected records →

Showing the latest 100 additions by PeptideScanner publication date; the complete connected record set remains available on the cross-source timeline. Most recent addition: November 15, 2026.

Record added

Leuprolide DailyMed SPL version 1

DailyMed lists Structured Product Labeling version 1 for the reviewed Leuprolide label family with a published date of 2023-09-01. PeptideScanner retained the exact versioned ZIP byte count and SHA-256 receipt without republishing its contents.

PeptideScanner change date
November 15, 2026
Cited source date
September 1, 2023
Evidence lane
Regulatory
Record added

Leuprolide DailyMed SPL version 10

DailyMed lists Structured Product Labeling version 10 for the reviewed Leuprolide label family with a published date of 2024-01-22. PeptideScanner retained the exact versioned ZIP byte count and SHA-256 receipt without republishing its contents.

PeptideScanner change date
November 15, 2026
Cited source date
January 22, 2024
Evidence lane
Regulatory
Record added

Leuprolide DailyMed SPL version 11

DailyMed lists Structured Product Labeling version 11 for the reviewed Leuprolide label family with a published date of 2024-02-12. PeptideScanner retained the exact versioned ZIP byte count and SHA-256 receipt without republishing its contents.

PeptideScanner change date
November 15, 2026
Cited source date
February 12, 2024
Evidence lane
Regulatory
Record added

Leuprolide DailyMed SPL version 13

DailyMed lists Structured Product Labeling version 13 for the reviewed Leuprolide label family with a published date of 2024-06-03. PeptideScanner retained the exact versioned ZIP byte count and SHA-256 receipt without republishing its contents.

PeptideScanner change date
November 15, 2026
Cited source date
June 3, 2024
Evidence lane
Regulatory
Record added

Leuprolide DailyMed SPL version 14

DailyMed lists Structured Product Labeling version 14 for the reviewed Leuprolide label family with a published date of 2024-08-30. PeptideScanner retained the exact versioned ZIP byte count and SHA-256 receipt without republishing its contents.

PeptideScanner change date
November 15, 2026
Cited source date
August 30, 2024
Evidence lane
Regulatory
Record added

Leuprolide DailyMed SPL version 16

DailyMed lists Structured Product Labeling version 16 for the reviewed Leuprolide label family with a published date of 2024-12-13. PeptideScanner retained the exact versioned ZIP byte count and SHA-256 receipt without republishing its contents.

PeptideScanner change date
November 15, 2026
Cited source date
December 13, 2024
Evidence lane
Regulatory
Record added

Leuprolide DailyMed SPL version 17

DailyMed lists Structured Product Labeling version 17 for the reviewed Leuprolide label family with a published date of 2025-02-17. PeptideScanner retained the exact versioned ZIP byte count and SHA-256 receipt without republishing its contents.

PeptideScanner change date
November 15, 2026
Cited source date
February 17, 2025
Evidence lane
Regulatory
Record added

Leuprolide DailyMed SPL version 18

DailyMed lists Structured Product Labeling version 18 for the reviewed Leuprolide label family with a published date of 2025-02-28. PeptideScanner retained the exact versioned ZIP byte count and SHA-256 receipt without republishing its contents.

PeptideScanner change date
November 15, 2026
Cited source date
February 28, 2025
Evidence lane
Regulatory
Record added

Leuprolide DailyMed SPL version 19

DailyMed lists Structured Product Labeling version 19 for the reviewed Leuprolide label family with a published date of 2026-05-11. PeptideScanner retained the exact versioned ZIP byte count and SHA-256 receipt without republishing its contents.

PeptideScanner change date
November 15, 2026
Cited source date
May 11, 2026
Evidence lane
Regulatory
Record added

Leuprolide DailyMed SPL version 4

DailyMed lists Structured Product Labeling version 4 for the reviewed Leuprolide label family with a published date of 2023-09-15. PeptideScanner retained the exact versioned ZIP byte count and SHA-256 receipt without republishing its contents.

PeptideScanner change date
November 15, 2026
Cited source date
September 15, 2023
Evidence lane
Regulatory
Record added

Leuprolide DailyMed SPL version 7

DailyMed lists Structured Product Labeling version 7 for the reviewed Leuprolide label family with a published date of 2023-12-18. PeptideScanner retained the exact versioned ZIP byte count and SHA-256 receipt without republishing its contents.

PeptideScanner change date
November 15, 2026
Cited source date
December 18, 2023
Evidence lane
Regulatory
Record added

ClinicalTrials.gov record NCT01674140

PeptideScanner retained ClinicalTrials.gov record NCT01674140 at 2026-11-14T22:56:28.992Z. Its registry update date was 2026-10-23, and PeptideScanner's reviewed identity mapping was leuprolide.

PeptideScanner change date
November 14, 2026
Cited source date
October 23, 2026
Evidence lane
Clinical trials
Record added

ClinicalTrials.gov record NCT05827081

PeptideScanner retained ClinicalTrials.gov record NCT05827081 at 2026-11-14T22:56:28.992Z. Its registry update date was 2026-11-13, and PeptideScanner's reviewed identity mapping was leuprolide.

PeptideScanner change date
November 14, 2026
Cited source date
November 13, 2026
Evidence lane
Clinical trials
Record added

ClinicalTrials.gov record NCT07848828

PeptideScanner retained ClinicalTrials.gov record NCT07848828 at 2026-11-14T22:56:28.992Z. Its registry update date was 2026-11-02, and PeptideScanner's reviewed identity mapping was leuprolide.

PeptideScanner change date
November 14, 2026
Cited source date
November 2, 2026
Evidence lane
Clinical trials
Record added

Federal Register notice 2026-17222

The Federal Register published notice 2026-17222, attributed to FDA and its parent HHS department, on 2026-08-24. Its official title is “Product-Specific Guidances; Draft and Revised Draft Guidances for Industry; Availability,” and PeptideScanner's exact reviewed identity mapping connects the document to Leuprolide and Octreotide.

PeptideScanner change date
November 14, 2026
Cited source date
August 24, 2026
Evidence lane
Regulatory
Record added

Leuprolide acetate, a GnRH agonist, preserves cerebellar integrity and motor coordination in a rat model of hepatic encephalopathy.

PubMed lists PMID 42962871 in Physiology & behavior as Journal Article, with publication-date metadata of 2026-10-30 (day precision). PeptideScanner associated the retained record with the identity slug leuprolide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

PeptideScanner change date
November 14, 2026
Cited source date
November 6, 2026
Evidence lane
Literature metadata
Record added

ClinicalTrials.gov record NCT07596212

PeptideScanner retained ClinicalTrials.gov record NCT07596212 at 2026-09-09T19:17:17.112Z. Its registry update date was 2026-08-24, and PeptideScanner's reviewed identity mapping was leuprolide.

PeptideScanner change date
September 9, 2026
Cited source date
August 24, 2026
Evidence lane
Clinical trials
Record added

ClinicalTrials.gov record NCT07801664

PeptideScanner retained ClinicalTrials.gov record NCT07801664 at 2026-09-09T19:17:17.074Z. Its registry update date was 2026-09-03, and PeptideScanner's reviewed identity mapping was leuprolide.

PeptideScanner change date
September 9, 2026
Cited source date
September 3, 2026
Evidence lane
Clinical trials
Record added

Failure to achieve castration levels in patients using leuprolide acetate in locally advanced prostate cancer.

PubMed lists PMID 16314038 in European urology as Journal Article, with publication-date metadata of 2005-11-15 (day precision). PeptideScanner associated the retained record with the identity slug leuprolide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

PeptideScanner change date
September 9, 2026
Cited source date
November 21, 2013
Evidence lane
Literature metadata
Record added

FDA enforcement report D-1178-2023

FDA's dated enforcement report D-1178-2023 lists Class III and source status Terminated for Tolmar, Inc. PeptideScanner connects the report to reviewed application NDA021379 through exact openFDA application-number annotations.

PeptideScanner change date
August 25, 2026
Cited source date
October 4, 2023
Evidence lane
Safety
Record added

FDA enforcement report D-1287-2014

FDA's dated enforcement report D-1287-2014 lists Class II and source status Terminated for AbbVie Inc. PeptideScanner connects the report to reviewed application NDA020517 through exact openFDA application-number annotations.

PeptideScanner change date
August 25, 2026
Cited source date
May 7, 2014
Evidence lane
Safety
Record added

FDA enforcement report D-1288-2014

FDA's dated enforcement report D-1288-2014 lists Class II and source status Terminated for AbbVie Inc. PeptideScanner connects the report to reviewed application NDA020517 through exact openFDA application-number annotations.

PeptideScanner change date
August 25, 2026
Cited source date
May 7, 2014
Evidence lane
Safety
Record added

FDA enforcement report D-1289-2014

FDA's dated enforcement report D-1289-2014 lists Class II and source status Terminated for AbbVie Inc. PeptideScanner connects the report to reviewed application NDA020263 through exact openFDA application-number annotations.

PeptideScanner change date
August 25, 2026
Cited source date
May 7, 2014
Evidence lane
Safety
Record added

FDA enforcement report D-1290-2014

FDA's dated enforcement report D-1290-2014 lists Class II and source status Terminated for AbbVie Inc. PeptideScanner connects the report to reviewed application NDA020708 through exact openFDA application-number annotations.

PeptideScanner change date
August 25, 2026
Cited source date
May 7, 2014
Evidence lane
Safety
Record added

FDA enforcement report D-1291-2014

FDA's dated enforcement report D-1291-2014 lists Class II and source status Terminated for AbbVie Inc. PeptideScanner connects the report to reviewed application NDA020517 through exact openFDA application-number annotations.

PeptideScanner change date
August 25, 2026
Cited source date
May 7, 2014
Evidence lane
Safety
Record added

Leuprolide DailyMed SPL version 10

DailyMed lists Structured Product Labeling version 10 for the reviewed Leuprolide label family with a published date of 2026-07-06. PeptideScanner retained the exact versioned ZIP byte count and SHA-256 receipt without republishing its contents.

PeptideScanner change date
August 22, 2026
Cited source date
July 6, 2026
Evidence lane
Regulatory
Record added

Leuprolide DailyMed SPL version 4

DailyMed lists Structured Product Labeling version 4 for the reviewed Leuprolide label family with a published date of 2022-11-07. PeptideScanner retained the exact versioned ZIP byte count and SHA-256 receipt without republishing its contents.

PeptideScanner change date
August 22, 2026
Cited source date
November 7, 2022
Evidence lane
Regulatory
Record added

Leuprolide DailyMed SPL version 5

DailyMed lists Structured Product Labeling version 5 for the reviewed Leuprolide label family with a published date of 2023-03-07. PeptideScanner retained the exact versioned ZIP byte count and SHA-256 receipt without republishing its contents.

PeptideScanner change date
August 22, 2026
Cited source date
March 7, 2023
Evidence lane
Regulatory
Record added

Leuprolide DailyMed SPL version 6

DailyMed lists Structured Product Labeling version 6 for the reviewed Leuprolide label family with a published date of 2024-11-18. PeptideScanner retained the exact versioned ZIP byte count and SHA-256 receipt without republishing its contents.

PeptideScanner change date
August 22, 2026
Cited source date
November 18, 2024
Evidence lane
Regulatory
Record added

Leuprolide DailyMed SPL version 7

DailyMed lists Structured Product Labeling version 7 for the reviewed Leuprolide label family with a published date of 2025-04-28. PeptideScanner retained the exact versioned ZIP byte count and SHA-256 receipt without republishing its contents.

PeptideScanner change date
August 22, 2026
Cited source date
April 28, 2025
Evidence lane
Regulatory
Record added

Leuprolide DailyMed SPL version 9

DailyMed lists Structured Product Labeling version 9 for the reviewed Leuprolide label family with a published date of 2025-12-29. PeptideScanner retained the exact versioned ZIP byte count and SHA-256 receipt without republishing its contents.

PeptideScanner change date
August 22, 2026
Cited source date
December 29, 2025
Evidence lane
Regulatory
Record added

Federal Register notice 05-20301

The Federal Register published notice 05-20301, attributed to FDA and its parent HHS department, on 2005-10-07. Its official title is “Solicitation of Public Review and Comment on Research Protocol: Gonadotropin-releasing Hormone Agonist Test in Disorders of Puberty,” and PeptideScanner's exact reviewed identity mapping connects the document to Leuprolide.

PeptideScanner change date
August 21, 2026
Cited source date
October 7, 2005
Evidence lane
Regulatory
Record added

Federal Register notice 05-20302

The Federal Register published notice 05-20302, attributed to FDA and its parent HHS department, on 2005-10-07. Its official title is “Pediatric Ethics Subcommittee of the Pediatric Advisory Committee; Notice of Meeting,” and PeptideScanner's exact reviewed identity mapping connects the document to Leuprolide.

PeptideScanner change date
August 21, 2026
Cited source date
October 7, 2005
Evidence lane
Regulatory
Record added

Federal Register notice 2011-14164

The Federal Register published notice 2011-14164, attributed to FDA and its parent HHS department, on 2011-06-08. Its official title is “Bristol-Myers Squibb Co. et al.; Withdrawal of Approval of 70 New Drug Applications and 97 Abbreviated New Drug Applications,” and PeptideScanner's exact reviewed identity mapping connects the document to Leuprolide.

PeptideScanner change date
August 21, 2026
Cited source date
June 8, 2011
Evidence lane
Regulatory
Record added

Federal Register notice 2012-1433

The Federal Register published notice 2012-1433, attributed to FDA and its parent HHS department, on 2012-01-25. Its official title is “Draft and Revised Draft Guidances for Industry Describing Product-Specific Bioequivalence Recommendations; Availability,” and PeptideScanner's exact reviewed identity mapping connects the document to Leuprolide and Octreotide.

PeptideScanner change date
August 21, 2026
Cited source date
January 25, 2012
Evidence lane
Regulatory
Record added

Federal Register notice 2014-07330

The Federal Register published notice 2014-07330, attributed to FDA and its parent HHS department, on 2014-04-02. Its official title is “Draft and Revised Draft Guidances for Industry Describing Product-Specific Bioequivalence Recommendations; Availability,” and PeptideScanner's exact reviewed identity mapping connects the document to Leuprolide and Octreotide.

PeptideScanner change date
August 21, 2026
Cited source date
April 2, 2014
Evidence lane
Regulatory
Record added

Federal Register notice 2014-19713

The Federal Register published notice 2014-19713, attributed to FDA and its parent HHS department, on 2014-08-20. Its official title is “Determination That LUPRON DEPOT-PED (Leuprolide Acetate for Depot Suspension), Injectable 3.75 Milligrams/Vial and 7.5 Milligrams/Vial; and LUPRON DEPOT-PED (Leuprolide Acetate for Depot Suspension), Injectable 7.5 Milligrams/Vial and 7.5 Milligrams/Vial, Were Not Withdrawn From Sale for Reasons of Safety or Effectiveness,” and PeptideScanner's exact reviewed identity mapping connects the document to Leuprolide.

PeptideScanner change date
August 21, 2026
Cited source date
August 20, 2014
Evidence lane
Regulatory
Record added

Federal Register notice 2014-23961

The Federal Register published notice 2014-23961, attributed to FDA and its parent HHS department, on 2014-10-08. Its official title is “Determination That LUPRON DEPOT (Leuprolide Acetate for Depot Suspension), Injectable 3.75 Milligrams/Vial Was Not Withdrawn From Sale for Reasons of Safety or Effectiveness,” and PeptideScanner's exact reviewed identity mapping connects the document to Leuprolide.

PeptideScanner change date
August 21, 2026
Cited source date
October 8, 2014
Evidence lane
Regulatory
Record added

Federal Register notice 2017-12908

The Federal Register published notice 2017-12908, attributed to FDA and its parent HHS department, on 2017-06-21. Its official title is “Wyeth Pharmaceuticals Inc. et al.; Withdrawal of Approval of 121 New Drug Applications and 161 Abbreviated New Drug Applications,” and PeptideScanner's exact reviewed identity mapping connects the document to Leuprolide and Octreotide.

PeptideScanner change date
August 21, 2026
Cited source date
June 21, 2017
Evidence lane
Regulatory
Record added

Federal Register notice 2018-02667

The Federal Register published notice 2018-02667, attributed to FDA and its parent HHS department, on 2018-02-09. Its official title is “Product-Specific Guidances; Draft and Revised Draft Guidances for Industry; Availability,” and PeptideScanner's exact reviewed identity mapping connects the document to Leuprolide.

PeptideScanner change date
August 21, 2026
Cited source date
February 9, 2018
Evidence lane
Regulatory
Record added

Federal Register notice 2019-11243

The Federal Register published notice 2019-11243, attributed to FDA and its parent HHS department, on 2019-05-30. Its official title is “Determination That LUPRON (Leuprolide Acetate) Injection, 1 Milligram/0.2 Milliliter, Was Not Withdrawn From Sale for Reasons of Safety or Effectiveness,” and PeptideScanner's exact reviewed identity mapping connects the document to Leuprolide.

PeptideScanner change date
August 21, 2026
Cited source date
May 30, 2019
Evidence lane
Regulatory
Record added

Federal Register notice 2021-18072

The Federal Register published notice 2021-18072, attributed to FDA and its parent HHS department, on 2021-08-23. Its official title is “Product-Specific Guidances; Draft and Revised Draft Guidances for Industry; Availability,” and PeptideScanner's exact reviewed identity mapping connects the document to Leuprolide and Semaglutide.

PeptideScanner change date
August 21, 2026
Cited source date
August 23, 2021
Evidence lane
Regulatory
Record added

Federal Register notice 2021-24431

The Federal Register published notice 2021-24431, attributed to FDA and its parent HHS department, on 2021-11-09. Its official title is “Product-Specific Guidances; Draft and Revised Draft Guidances for Industry; Availability,” and PeptideScanner's exact reviewed identity mapping connects the document to Glucagon and Leuprolide.

PeptideScanner change date
August 21, 2026
Cited source date
November 9, 2021
Evidence lane
Regulatory
Record added

Federal Register notice 2022-03248

The Federal Register published notice 2022-03248, attributed to FDA and its parent HHS department, on 2022-02-18. Its official title is “Product-Specific Guidances; Draft and Revised Draft Guidances for Industry; Availability,” and PeptideScanner's exact reviewed identity mapping connects the document to Leuprolide.

PeptideScanner change date
August 21, 2026
Cited source date
February 18, 2022
Evidence lane
Regulatory
Record added

Federal Register notice 2023-03364

The Federal Register published notice 2023-03364, attributed to FDA and its parent HHS department, on 2023-02-17. Its official title is “Product-Specific Guidances; Draft and Revised Draft Guidances for Industry; Availability,” and PeptideScanner's exact reviewed identity mapping connects the document to Afamelanotide, Glucagon, Leuprolide and Vosoritide.

PeptideScanner change date
August 21, 2026
Cited source date
February 17, 2023
Evidence lane
Regulatory
Record added

Federal Register notice 2024-04218

The Federal Register published notice 2024-04218, attributed to FDA and its parent HHS department, on 2024-02-29. Its official title is “Determination of Regulatory Review Period for Purposes of Patent Extension; CAMCEVI,” and PeptideScanner's exact reviewed identity mapping connects the document to Leuprolide.

PeptideScanner change date
August 21, 2026
Cited source date
February 29, 2024
Evidence lane
Regulatory
Record added

Federal Register notice 2024-08657

The Federal Register published notice 2024-08657, attributed to FDA and its parent HHS department, on 2024-04-23. Its official title is “PAI Holdings, LLC DBA Pharmaceutical Associates, Inc., et al.; Withdrawal of Approval of 23 New Drug Applications,” and PeptideScanner's exact reviewed identity mapping connects the document to Leuprolide.

PeptideScanner change date
August 21, 2026
Cited source date
April 23, 2024
Evidence lane
Regulatory
Record added

Federal Register notice 98-13045

The Federal Register published notice 98-13045, attributed to FDA and its parent HHS department, on 1998-05-18. Its official title is “Environmental Assessments and Findings of No Significant Impact,” and PeptideScanner's exact reviewed identity mapping connects the document to Leuprolide.

PeptideScanner change date
August 21, 2026
Cited source date
May 18, 1998
Evidence lane
Regulatory
Record added

Federal Register notice E9-13272

The Federal Register published notice E9-13272, attributed to FDA and its parent HHS department, on 2009-06-08. Its official title is “Draft and Revised Draft Guidances for Industry Describing Product-Specific Bioequivalence Recommendations; Availability,” and PeptideScanner's exact reviewed identity mapping connects the document to Leuprolide.

PeptideScanner change date
August 21, 2026
Cited source date
June 8, 2009
Evidence lane
Regulatory
Record added

Treatment of prostatic cancer with TAP-144-SR, a depot preparation of LH-RH agonist (leuprolide).

PubMed lists PMID 16312848 in Journal of chemotherapy (Florence, Italy) as Journal Article, with publication-date metadata of 1989-07 (month precision). PeptideScanner associated the retained record with the identity slug leuprolide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

PeptideScanner change date
August 16, 2026
Cited source date
November 21, 2013
Evidence lane
Literature metadata
Record added

ClinicalTrials.gov record NCT05896293

PeptideScanner retained ClinicalTrials.gov record NCT05896293 at 2026-08-10T18:10:03.920Z. Its registry update date was 2026-07-13, and PeptideScanner's reviewed identity mapping was leuprolide.

PeptideScanner change date
August 14, 2026
Cited source date
July 13, 2026
Evidence lane
Clinical trials
Record added

ClinicalTrials.gov record NCT07455903

PeptideScanner retained ClinicalTrials.gov record NCT07455903 at 2026-08-13T05:52:27.015Z. Its registry update date was 2026-08-06, and PeptideScanner's reviewed identity mapping was leuprolide.

PeptideScanner change date
August 14, 2026
Cited source date
August 6, 2026
Evidence lane
Clinical trials
Record added

Leuprolide acetate therapy in LH-dependent Cushing's syndrome: in vivo and in vitro observations.

PubMed lists PMID 15685898 in The Netherlands journal of medicine as Case Reports, Journal Article, with publication-date metadata of 2004-12 (month precision). PeptideScanner associated the retained record with the identity slug leuprolide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

PeptideScanner change date
August 14, 2026
Cited source date
November 21, 2013
Evidence lane
Literature metadata
Record added

The role of leuprolide acetate therapy in triggering auto-immune thyroiditis.

PubMed lists PMID 15689930 in The Journal of pediatrics as Comment, Letter, with publication-date metadata of 2005-02 (month precision). PeptideScanner associated the retained record with the identity slug leuprolide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

PeptideScanner change date
August 14, 2026
Cited source date
November 21, 2013
Evidence lane
Literature metadata
Record added

LC determination of leuprolide component amino acids in injectable solution by phanquinone pre-column derivatization labelling procedure.

PubMed lists PMID 15862697 in Journal of pharmaceutical and biomedical analysis as Journal Article, Research Support, Non-U.S. Gov't, with publication-date metadata of 2005-04-29 (day precision). PeptideScanner associated the retained record with the identity slug leuprolide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

PeptideScanner change date
August 14, 2026
Cited source date
November 21, 2013
Evidence lane
Literature metadata
Record added

Leuprolide acetate given by a subcutaneous extended-release injection: less of a pain?

PubMed lists PMID 16111462 in Expert review of anticancer therapy as Journal Article, Review, with publication-date metadata of 2005-08 (month precision). PeptideScanner associated the retained record with the identity slug leuprolide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

PeptideScanner change date
August 14, 2026
Cited source date
November 21, 2013
Evidence lane
Literature metadata
Record added

ClinicalTrials.gov record NCT00002580

PeptideScanner retained ClinicalTrials.gov record NCT00002580 at 2026-07-30T21:55:56.626Z. Its registry update date was 2013-11-06, and PeptideScanner's reviewed identity mapping was leuprolide.

PeptideScanner change date
August 13, 2026
Cited source date
November 6, 2013
Evidence lane
Clinical trials
Record added

ClinicalTrials.gov record NCT00002582

PeptideScanner retained ClinicalTrials.gov record NCT00002582 at 2026-07-30T21:55:56.631Z. Its registry update date was 2013-08-02, and PeptideScanner's reviewed identity mapping was leuprolide.

PeptideScanner change date
August 13, 2026
Cited source date
August 2, 2013
Evidence lane
Clinical trials
Record added

ClinicalTrials.gov record NCT00002881

PeptideScanner retained ClinicalTrials.gov record NCT00002881 at 2026-07-30T22:25:23.114Z. Its registry update date was 2010-11-09, and PeptideScanner's reviewed identity mapping was leuprolide.

PeptideScanner change date
August 13, 2026
Cited source date
November 9, 2010
Evidence lane
Clinical trials
Record added

ClinicalTrials.gov record NCT00003124

PeptideScanner retained ClinicalTrials.gov record NCT00003124 at 2026-07-30T21:54:46.538Z. Its registry update date was 2014-01-06, and PeptideScanner's reviewed identity mapping was leuprolide.

PeptideScanner change date
August 13, 2026
Cited source date
January 6, 2014
Evidence lane
Clinical trials
Record added

ClinicalTrials.gov record NCT00003394

PeptideScanner retained ClinicalTrials.gov record NCT00003394 at 2026-07-30T21:55:56.623Z. Its registry update date was 2013-06-24, and PeptideScanner's reviewed identity mapping was leuprolide.

PeptideScanner change date
August 13, 2026
Cited source date
June 24, 2013
Evidence lane
Clinical trials
Record added

ClinicalTrials.gov record NCT00004311

PeptideScanner retained ClinicalTrials.gov record NCT00004311 at 2026-07-30T22:50:58.187Z. Its registry update date was 2005-06-24, and PeptideScanner's reviewed identity mapping was leuprolide.

PeptideScanner change date
August 13, 2026
Cited source date
June 24, 2005
Evidence lane
Clinical trials
Record added

ClinicalTrials.gov record NCT00004344

PeptideScanner retained ClinicalTrials.gov record NCT00004344 at 2026-07-30T22:50:58.186Z. Its registry update date was 2005-06-24, and PeptideScanner's reviewed identity mapping was leuprolide.

PeptideScanner change date
August 13, 2026
Cited source date
June 24, 2005
Evidence lane
Clinical trials
Record added

ClinicalTrials.gov record NCT00004426

PeptideScanner retained ClinicalTrials.gov record NCT00004426 at 2026-07-30T21:43:54.469Z. Its registry update date was 2015-03-26, and PeptideScanner's reviewed identity mapping was leuprolide.

PeptideScanner change date
August 13, 2026
Cited source date
March 26, 2015
Evidence lane
Clinical trials
Record added

ClinicalTrials.gov record NCT00004436

PeptideScanner retained ClinicalTrials.gov record NCT00004436 at 2026-07-30T21:43:54.456Z. Its registry update date was 2015-03-25, and PeptideScanner's reviewed identity mapping was leuprolide.

PeptideScanner change date
August 13, 2026
Cited source date
March 25, 2015
Evidence lane
Clinical trials
Record added

ClinicalTrials.gov record NCT00004438

PeptideScanner retained ClinicalTrials.gov record NCT00004438 at 2026-07-30T21:43:54.452Z. Its registry update date was 2015-03-25, and PeptideScanner's reviewed identity mapping was leuprolide.

PeptideScanner change date
August 13, 2026
Cited source date
March 25, 2015
Evidence lane
Clinical trials
Record added

ClinicalTrials.gov record NCT00004771

PeptideScanner retained ClinicalTrials.gov record NCT00004771 at 2026-07-30T22:50:58.183Z. Its registry update date was 2005-06-24, and PeptideScanner's reviewed identity mapping was leuprolide.

PeptideScanner change date
August 13, 2026
Cited source date
June 24, 2005
Evidence lane
Clinical trials
Record added

ClinicalTrials.gov record NCT00063310

PeptideScanner retained ClinicalTrials.gov record NCT00063310 at 2026-07-30T22:26:45.017Z. Its registry update date was 2009-12-11, and PeptideScanner's reviewed identity mapping was leuprolide.

PeptideScanner change date
August 13, 2026
Cited source date
December 11, 2009
Evidence lane
Clinical trials
Record added

ClinicalTrials.gov record NCT00170157

PeptideScanner retained ClinicalTrials.gov record NCT00170157 at 2026-07-30T21:24:24.228Z. Its registry update date was 2017-05-15, and PeptideScanner's reviewed identity mapping was leuprolide.

PeptideScanner change date
August 13, 2026
Cited source date
May 15, 2017
Evidence lane
Clinical trials
Record added

ClinicalTrials.gov record NCT00225420

PeptideScanner retained ClinicalTrials.gov record NCT00225420 at 2026-07-30T21:24:24.228Z. Its registry update date was 2017-06-01, and PeptideScanner's reviewed identity mapping was leuprolide.

PeptideScanner change date
August 13, 2026
Cited source date
June 1, 2017
Evidence lane
Clinical trials
Record added

ClinicalTrials.gov record NCT00349258

PeptideScanner retained ClinicalTrials.gov record NCT00349258 at 2026-07-30T22:49:18.182Z. Its registry update date was 2006-07-06, and PeptideScanner's reviewed identity mapping was leuprolide.

PeptideScanner change date
August 13, 2026
Cited source date
July 6, 2006
Evidence lane
Clinical trials
Record added

ClinicalTrials.gov record NCT00380406

PeptideScanner retained ClinicalTrials.gov record NCT00380406 at 2026-07-30T21:24:24.229Z. Its registry update date was 2017-04-05, and PeptideScanner's reviewed identity mapping was leuprolide.

PeptideScanner change date
August 13, 2026
Cited source date
April 5, 2017
Evidence lane
Clinical trials
Record added

ClinicalTrials.gov record NCT00429494

PeptideScanner retained ClinicalTrials.gov record NCT00429494 at 2026-07-30T21:55:56.622Z. Its registry update date was 2013-07-09, and PeptideScanner's reviewed identity mapping was leuprolide.

PeptideScanner change date
August 13, 2026
Cited source date
July 9, 2013
Evidence lane
Clinical trials
Record added

ClinicalTrials.gov record NCT00454571

PeptideScanner retained ClinicalTrials.gov record NCT00454571 at 2026-07-30T21:38:42.855Z. Its registry update date was 2016-02-10, and PeptideScanner's reviewed identity mapping was leuprolide.

PeptideScanner change date
August 13, 2026
Cited source date
February 10, 2016
Evidence lane
Clinical trials
Record added

ClinicalTrials.gov record NCT00500110

PeptideScanner retained ClinicalTrials.gov record NCT00500110 at 2026-07-30T21:42:40.792Z. Its registry update date was 2015-04-28, and PeptideScanner's reviewed identity mapping was leuprolide.

PeptideScanner change date
August 13, 2026
Cited source date
April 28, 2015
Evidence lane
Clinical trials